Research Topics
| Martin AringerSummaryAffiliation: Medical University of Vienna Country: Austria Publications
| Collaborators
|
Detail Information
Publications
[Systemic lupus erythematosus--activity and outcome]M Aringer
Klinische Abt für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien
Z Rheumatol 65:103-6, 108-9. 2006..The combination of shorter studies for defining hopeful strategies followed by long definitive studies, appears to be the best option at present...- Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosusMartin Aringer
Medical University of Vienna, Vienna, Austria
Arthritis Rheum 56:274-9. 2007..To analyze changes in autoantibodies occurring in patients with systemic lupus erythematosus (SLE) treated with 4 infusions of the chimeric anti-tumor necrosis factor alpha (TNFalpha) antibody infliximab... - ICF core sets: how to specify impairment and function in systemic lupus erythematosusM Aringer
Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
Lupus 15:248-53. 2006..The development of these SLE ICF Core Sets is designed to be an inclusive, open, worldwide process. We therefore invite both SLE clinical experts and SLE patients to participate actively... - Cytokine expression in lupus kidneysM Aringer
Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Lupus 14:13-8. 2005..This may help solve discrepancies between different murine models of the disease and provide a better rationale for targeting certain cytokines in human SLE... - Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label studyMartin Aringer
Internal Medicine III, Medical University of Vienna, Vienna, Austria
Arthritis Rheum 50:3161-9. 2004..This finding, coupled with the clinical improvement in the inflammatory manifestations of the disease, indicates that further study in larger controlled trials is warranted... - Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cellsThomas Karonitsch
Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
Arthritis Rheum 60:1463-71. 2009.... - Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exerciseBettina Bauernfeind
Vienna Medical University, Vienna, Austria
Arthritis Rheum 61:21-8. 2009..To identify the most important and relevant concepts of daily functioning from the perspective of patients with systemic lupus erythematosus (SLE)... - Interferon signals and monocytic sensitization of the interferon-γ signaling pathway in the peripheral blood of patients with rheumatoid arthritisThomas Karonitsch
Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
Arthritis Rheum 64:400-8. 2012..The aim of this study was to determine the systemic activity of the IFN/STAT-1 signaling pathway in the peripheral blood cells of patients with RA... - Does mixed connective tissue disease exist? YesMartin Aringer
Department of Rheumatology, Internal Medicine III, Medical University of Vienna, AKH, Waehringer Guertel 18 20, A 1090 Vienna, Austria
Rheum Dis Clin North Am 31:411-20, v. 2005..The authors believe that the concept is useful in daily practice and accurate in the idea that MCTD constitutes a disease entity of its own... - Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health statusTanja A Stamm
Vienna Medical University, Vienna, Austria
Arthritis Rheum 57:1287-95. 2007..To explore the array of concepts important to patients with chronic systemic lupus erythematosus (SLE) and to compare these with instruments assessing disease activity, damage, and health status... - Engulfed cell remnants, and not cells undergoing apoptosis, constitute the LE-cell phenomenonEva Feierl
Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
Autoimmunity 40:315-21. 2007.... - Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacyGeorg H Stummvoll
Deptartment of Rheumatology, University of Vienna, Vienna General Hospital, Vienna, Austria
Wien Klin Wochenschr 116:716-24. 2004..Immunoadsorption (IAS), in contrast, selectively removes Ig and IC and may thus be safer. We therefore investigated the rate of infections in SLE patients who were undergoing long-term IAS... - Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literatureGeorg Schett
Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
J Clin Microbiol 43:2537-41. 2005..We review the literature of articular listeriosis and discuss the role of tumor necrosis factor blockade in precipitating listeriosis... - Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findingsClaudia Schueller-Weidekamm
Department of Diagnostic Radiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
Eur J Radiol 62:437-43. 2007..To explore the typical sonographic features of gray-scale and Power Doppler of acute and chronic gouty arthritis in conjunction with radiographic, clinical, and laboratory findings... - IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational studyG H Stummvoll
Department of Rheumatology, Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
Ann Rheum Dis 64:1015-21. 2005.... - Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic interventionM Aringer
Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Lupus 13:344-7. 2004..Interferon (IFN)-gamma, interleukin (IL)-18, IL-6 and possibly IL-1 are increased in SLE and likewise involved in the inflammatory process. Specific therapeutic agents for blocking these cytokines should be available in the near future... - SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosusMartin Aringer
Department of Rheumatology, Internal Medicine III, University of Vienna, Austria
Arthritis Res Ther 5:172-7. 2003..Therefore, TNF blockade probably constitutes an efficacious therapeutic option... - Anti-cytokine therapy in systemic lupus erythematosusJ S Smolen
Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Lupus 14:189-91. 2005..Since new therapeutic agents may soon offer many ways to influence the process, controlled clinical trials following open-label safety studies are of central importance to arrive at optimized therapies for SLE patients... - Characterisation of cellular and humoral autoimmune responses to histone H1 and core histones in human systemic lupus erythaematosusG H Stummvoll
G Steiner, Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Wahringer Gurtel 18, A 1090 Vienna, Austria
Ann Rheum Dis 68:110-6. 2009.... - Increased bioactive TNF in human systemic lupus erythematosus: associations with cell deathM Aringer
Department of Rheumatology, Internal Medicine II, University of Vienna, Austria
Lupus 11:102-8. 2002..Peripheral blood lymphocytes of SLE patients express functional TNF receptors. Finally, associations with cell death and CD95 receptors suggest that TNF may be pathogenic in SLE... - Serum interleukin-15 is elevated in systemic lupus erythematosusM Aringer
Department of Rheumatology, Internal Medicine III, University of Vienna, Austria
Rheumatology (Oxford) 40:876-81. 2001..Both lymphocyte CD25 and Bcl-2 expression significantly correlated with serum IL-15 and were increased by recombinant IL-15. CONCLUSION: Serum IL-15 may in part be responsible for the immunological abnormalities seen in active SLE... - Periodic fever syndromes--a clinical overviewMartin Aringer
Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
Acta Med Austriaca 31:8-12. 2004..Therefore this review will concentrate on FMF and TRAPS, the latter being a very rare disease, while the former has become somewhat more common in mid-Europe as a result of migration... - High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockersJosef Hermann
Ann Rheum Dis 66:561-2. 2007 - The role of tumor necrosis factor-alpha in systemic lupus erythematosusMartin Aringer
Division of Rheumatology, Department of Medicine III, University Clinical Center Carl Gustav Carus, Technical University of Dresden, Fetscherstrasse 74, 01307 Dresden, Germany
Arthritis Res Ther 10:202. 2008..At the same time, open-label data suggest that TNF blockade suppresses inflammatory manifestations of SLE, and long-term benefit was seen in patients with lupus nephritis. A controlled clinical trial is under way... - Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formationJohannes Grisar
Department of Internal Medicine III, University of Vienna, Austria
J Rheumatol 29:1430-6. 2002..To test if markers of bone metabolism are altered in patients with seronegative spondyloarthropathies (SSpA)... - Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosusMartin Aringer
University Clinical Center Carl Gustav Carus, Technical University of Dresden, Division of Rheumatology, Department of Medicine III, Fetscherstrasse 74, 01307 Dresden, Germany
Expert Opin Drug Saf 7:411-9. 2008..There is still unmet medical need in the therapy of severe organ manifestations of patients with systemic lupus erythematosus (SLE). Therapeutic agents targeting pro-inflammatory cytokines may be an interesting option... - Engineering anticancer T cells for extended functional longevityGraham Pawelec
Center for Medical Research, ZMF, University of Tubingen Medical School, Waldhornlestrasse 22, D 72072 Tuebingen, Germany
Ann N Y Acad Sci 1019:178-85. 2004.... - Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and coEsther Jimenez-Boj
Technical University Dresden, Dresden, Germany
Arthritis Rheum 58:1226-36. 2008.... - New treatments for SLE: cell-depleting and anti-cytokine therapiesJennifer H Anolik
Allergy, Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Best Pract Res Clin Rheumatol 19:859-78. 2005..Moreover, many additional cytokines, such as interleukin (IL)-6, IL-18, and the type I interferons, represent interesting future targets... - SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and goutVeronique Vitart
MRC Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, UK
Nat Genet 40:437-42. 2008..SLC2A9 is a known fructose transporter, and we now show that it has strong uric acid transport activity in Xenopus laevis oocytes... - [Cyclooxygenase 2 selective antirheumatic analgesics]Martin Aringer
Klinische Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin III, Wahringer Gurtel 18 20, A 1090 Wien
Wien Med Wochenschr 153:100-3. 2003..5 mg is sufficient for the control of less pronounced pain and thus not exceeded. The gastrointestinal safety of nimesulide can not be sufficiently evaluated based on the available clinical data... - The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosisLaszlo Czirjak
Department of Immunology and Rheumatology, University of Pecs, H 7621 Pecs, Irgalmasok u 1, Hungary
Ann Rheum Dis 66:966-9. 2007..To evaluate the ability to teach scleroderma experts and young rheumatologists to perform the modified Rodnan skin score test...